Mizuho lowered the firm’s price target on Corteva to $74 from $76 and keeps a Buy rating on the shares. The analyst acknowledges risks into the company’s Q2 report, but believes investors are already pricing in substantial de-stocking headwinds, rendering the stock’s risk/reward in the low-mid $50 per share range as a “very attractive” long-term entry point.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CTVA:
- Evogene’s Lavie Bio announces licensing agreement with Corteva
- Corteva price target lowered to $66 from $73 at RBC Capital
- Corteva price target lowered to $68 from $70 at KeyBanc
- EU policy shift on gene editing likely positive for Corteva, says Jefferies
- TipRanks ‘Perfect 10’ List: These 2 Top-Rated Stocks Tick All the Boxes